Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy for HIV Remission
NCT04357821Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2020
- Primary completion
- Jan 2024
- Modality
- Antisense DNA, Viral Vector Vaccines, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HIV-1 gag DNA, MVA/HIV62B, VRC07-523LS, zinlirvimab and lefitolimod in human immunodeficiency virus infection (HIV), sponsored by University of California, San Francisco. Primary endpoints: Grade 3 or Greater Adverse Event Count and Proportion of Participants Achieving Post-treatment Control. Started Aug 2020; status: completed.
02
Drugs
HIV-1 gag DNAMVA/HIV62BVRC07-523LSzinlirvimablefitolimod
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04357821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357821.